Skip to main content
Figure 2 | BMC Cancer

Figure 2

From: Expressions of MUC1 and vascular endothelial growth factor mRNA in blood are biomarkers for predicting efficacy of gefitinib treatment in non-small cell lung cancer

Figure 2

Changes of MUC1 and VEGF mRNA levels in blood of NSCLC patients. (A to C) Changes of MUC1 mRNA levels between before (B0) and 4 weeks after gefitinib treatment (B4w) in blood of NSCLC patients with partial response (PR), stable disease (SD) and progressive disease (PD). (D to F) Changes in blood VEGF mRNA levels between B0 and B4w time points in NSCLC patients with PR, SD and PD.

Back to article page
\